Cullinan Therapeutics at UBS conference: multiple catalysts ahead
Cullinan Therapeutics recently presented its portfolio of clinical-stage T-cell engagers at the UBS Global Biopharma Conference 2026. The company's focus spans immunology and oncology, with three key programs: CLN-978, CLN-049, and velinotamig.
CLN-978, a CD19 T-cell engager, demonstrated early signs of deep B-cell depletion and remission in autoimmune diseases. Preliminary data from about 20 patients is anticipated in December. CLN-049, a FLT3 T-cell engager, achieved a 31% composite response rate in relapsed or refractory AML, and Phase II enrollment has commenced. Velinotamig, a BCMA T-cell engager, showed encouraging results in lupus, with responses at low doses and favorable cytokine release syndrome management.
Cullinan's CEO, Nadim Ahmed, expressed confidence in the company's leading portfolio and an exciting period ahead, with multiple milestones in the coming weeks and months. The company is targeting deeper remission, durability, safety, and patient selection for each program.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.